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ABSTRACT: An ethyl acetate extract of Psiadia arguta leaves showed in vitro antiplasmodial activity against 
Plasmodium falciparum with IC50 values of 12.3 ± 2.4 µg∕mL (3D7 strain) and 13.5 ± 3.4 µg∕mL (W2 strain). 
Phytochemical investigation led to the isolation and characterization of 16 compounds including four new 
diterpenoids: labdan-8α-ol-15-yl-(formate) (1), labdan-8α-ol-15-yl-(2- methylbutanoate) (2), labdan-8α-ol-15-
yl-(3-methylpentanoate) (3), and labdan- 8α-ol-15-yl-(labdanolate) (4). The latter compounds were 
characterized by spectroscopic methods (1D and 2D NMR, HRMS, and IR). The in vitro antiplasmodial activities 
of all compounds were evaluated. The known compounds labdan-13(E)-en-8α-ol-15-yl acetate (5), labdan-8α-
ol-15-yl acetate (6), 13-epi-sclareol (7), labdan-13(E)-ene-8α,15-diol (8), and (8R,13S)-labdane- 8α,15-diol (9) 
exhibited antiplasmodial effects, with IC50 values of 29.1, 33.2, 35.0, 36.6, and 22.2 µM, respectively
 
The genus Psiadia (Asteraceae) consists of approximately 60 species mainly found in Madagascar and the 
Mascarene Islands (La Reunion, Mauritius, and Rodrigues).1 Psiadia arguta (Pers.) Voigt, commonly known as 
“Baume de l’île Plate”, is endemic to Mauritius and can be found on Ilot Gabriel, a small islet off Mauritius’s 
north coast. This species is used traditionally for treatment of pulmonary infections, respiratory disorders, 
cough, and indigestion and is also employed to heal minor wounds and burns.2,3 Previous pharmacological 
investigations of P. arguta extracts revealed several biological properties including antimicrobial,4 anti- 
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inflammatory,5,6 antiplasmodial,6 and cytotoxic6 effects. Despite its biological potential, the phytochemistry of 
P. arguta has not previously been investigated, and thus this plant was selected for bioassay-guided 
fractionation and isolation of its antiplasmodial constituents. We herein report the isolation, structure 
elucidation, and in vitro antiplasmodial activity of four new (1-4) and 12 known diterpenoids from the EtOAc 
(ethyl acetate) extract of P. arguta leaves. 
The P. arguta EtOAc leaf extract (yield 12%) was subjected to normal-phase chromatographic separation and 
yielded 18 fractions. The antiplasmodial activity of each fraction was evaluated. The promising antiplasmodial 
fractions F4, F6, F7, and F9 with IC50 values of 16.3, 8.8, 13.9, and 9.8 μg∕mL, respectively, were further purified 
by semipreparative HPLC. The major compounds of the crude extract of P. arguta were found in fractions F11, 
F14, F15, and F18. These fractions were also subjected to purification of the major compounds. Column 
chromatography (CC) and repetitive reversed-phase preparative HPLC afforded the isolation of four new 
diterpenoids (1-4) and 12 known terpenoids. The latter were identified by comparison with published 
spectroscopic data as β-amyrin,7 α-amyrin,7 labdan-13(E)-en-8α-ol-15-yl acetate (5),8 labdan-8α-ol-15-yl 
acetate (6),9 anticopalic acid,10 physanicandiol and 14-epi-physanicandiol,11 13-epi- sclareol (7),12 labdan-13(E)-
ene-8α,15-diol (8),13 (8R,13S)- labdane-8α,15-diol (9),14 labdanolic acid,15 and labdan-8(20)- en-15-ol.16 To the 
best of our knowledge, this is the first report concerning the isolation of these compounds from P. arguta. The 
structures of the new compounds 1-4 were elucidated by the analysis of their 1D and 2D NMR and IR spectra 
and MS data and are described below. 
 




Labdan-8α-ol-15-yl-(formate) (1) showed a [M + Na]+ peak at m/z 361.2713 (calcd for C21H38O3Na, 361.2713) in 
the HRESIMS, indicating a molecular formula of C21H38O3 and suggesting the occurrence of three degrees of 
unsaturation. The IR spectrum exhibited a broad band at 3436 cm-1, characteristic of a hydroxy group, and a 
band at 1728 cm-1, characteristic of the carbonyl of the formate ester function. Comparison of the 
spectroscopic data (HRMS, NMR, IR) of 1 to those of the diterpenoid labdan-8α-ol-15-yl acetate9 (6) (C22H40O3) 
indicated substantial similarities between these two compounds, suggesting that compound 1 has one methyl 
group less than labdan-8α-ol-15-yl acetate (6).  
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The 1H, 13C, and HMBC NMR spectra revealed resonances and 2,3JHC correlations consistent with those of an 
acetate moiety (δC 171.08 for C-1' and δΗ 2.00 for H-2') attached to C-15 in compound 6, whereas in compound 
1, the signals of C-1' (δC 161.4) linked to one proton H-1' (δΗ 8.05, singlet) supported a formate moiety also 
attached to C-15 (Table 1). This information was confirmed by the HMBC cross-peak between H-15 (δΗ 4.25 and 
4.18) and C-1' (δC 161.4) (Figure 1). Therefore, 1 was assigned as labdan-8α-ol-15-yl-(formate). 
The molecular formula of labdan-8α-ol-15-yl-(2-methylbu- tanoate) (2) was determined to be C25H46O3 by 
HRESIMS analysis, which showed a [M + Na]+ peak at m/z 417.3337 (calcd for C25H46O3Na, 417.3339). This 
suggested the presence of three degrees of unsaturation. The IR spectrum exhibited a broad band at 3504 cm-1 
that was indicative of the presence of a hydroxy group and two bands at 1734 and 1184 cm-1, characteristic of 
an ester function. Comparison of the spectroscopic data (HRMS, NMR, IR) of 2 to those of labdan- 8α-ol-15-yl-
(formate) (1) (C21H28O3) indicated substantial similarities between these two compounds, suggesting that 
compound 2 has one butyl group more than labdan-8α-ol-15- yl-(formate) (1). Inspection of 1H and 13C NMR 
data (Table 1) suggested that C-2' is a methine group (δC 41.3 and δΗ 2.35), C-3' is a methylene (δC 26.9 and δΗ 
1.67 and 1.44), and C-4' (δc 11.8 and δΗ 0.90) and C-5' (δc 16.8 and δΗ 1.13) are two methyl groups. With the aid of 
COSY and HMBC experiments, a 2-methylbutanoate moiety was identified by further analysis of the remaining 
1H NMR resonances [δΗ 2.35 (1H, sext, J = 7.0 Hz, H-2'), 1.67 (1H, ov, H-3'a), 1.44 (1H, ov, H-3'b), 1.13 (3H, d, J = 
7.4 Hz, H-5'), and 0.90 (3H, t, J = 7.4 Hz, H-4')] and by cross-peaks between H-2' (δΗ 2.35), H- 3' (δΗ 1.67 and 1.44), 
H-5' (δΗ 1.13), and C-1' (δC 177.1) (Figure 1). This 2-methylbutanoate moiety was assigned at the C-15 position, 
based on the HMBC cross-peak between H-15 (δΗ 4.15 and 4.06) and C-1' (δC 177.1) (Figure 1). 
Labdan-8α-ol-15-yl-(3-methylpentanoate) (3) exhibited a molecular formula of C26H48O3, as determined by its 
13C NMR and HRESIMS data (molecular ion at m/z 431.3493 [M + Na]+; calcd for C26H48O3Na 431.3496). 
Comparison of the spectroscopic data (HRMS, NMR, IR) of 3 with those of 2 (C25H46O3) indicated that both 
compounds have almost the same skeleton and revealed that compound 3 has an amyl group at the C-15 
position instead of a butyl group as in compound 2. Analysis of the 1H and 13C NMR data indicated that this 
amyl chain contains one methine C-3' (δc 32.1 and δΗ 1.87), two methylenes C-2' (δC 41.8 and δΗ 2.09 and 2.29) 
and C-4' (δC 29.5 and δΗ 1.22 and 1.36), and two methyls C5' (δC 11.4 and δΗ 0.89) and C-6' (δC 19.4 and δΗ 0.92). 
The amyl group could be assigned to 3-methylpentanoate by analysis of 2D NMR spectroscopic data including 
COSY and HMBC experiments. 
Labdan-8α-ol-15-yl-(labdanolate) (4) showed a [M + Na]+ peak at m/z 639.5328 (calcd for C40H72O4Na, 639.5323) 
in the HRESIMS, indicating a molecular formula of C40H72O4 and suggesting the occurrence of five degrees of 
unsaturation. Its IR spectrum exhibited similarities (bands at 3447, 1717, and 1183 cm-1) to those of 2 and 3, 
suggesting the presence of hydroxy groups and ester functions. The structure elucidation of 4 was established 
by comparison of its NMR data to those of 3, with both exhibiting substantial similarities. The main difference 
was found for the signal of the methyl C-5' (δc 11.4 and δΗ 0.89) in compound 3, which corresponded to the 
methylene C-11' (δc 20.3 and δΗ 1.28 and 1.37) in the case of compound 4. Thus, this information suggested that 
compound 4 has a substituent at the C-11' position in accordance with a molecular mass of 209.1905 
(corresponding to a molecular formula of C14H25O). Moreover, duplicated signals of all carbons of the bicyclic 
labdane skeleton were apparent in the 13C NMR spectrum, establishing the substitution at the C-11' position as 
an identical bicyclic ring. The attachment of the latter at the C-11' position was confirmed by a COSY 
correlation between H-11' (δΗ 1.37 and 1.28) and H-9' (δΗ 1.00) and HMBC correlations between H-12' (δΗ 1.45 
and 1.28) and H-9' (δΗ 1.00) and C-11' (δC20.3) (Figure 1). 
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Table 1. 1H (600 MHz) and 13C (150 MHz) NMR Data for Compounds 1-4 (CDCl3 at 300 K) 
 1 2 3 4 
position δC, type 
δH, mult 
(J in Hz) δC, type 
δH, mult 
(J in Hz) δC, type 
δH, mult 




(J in Hz) 
1 39.9, CH2 1.61, ov;a 0.91, td 
(13.1, 3.4) 
39.9, CH2 1.60, ov; 0.93, ov 39.9, CH2 1.61, ov; 0.93, td 
 (13.1, 3.4) 
39.8, CH2 1.61, ov; 0.93, ov 
2 18.6, CH2 1.59, ov; 1.42, ov 18.6, CH2 1.58, ov; 1.42, ov 18.6, CH2 1.58, ov; 1.42, ov 18.6, CH2 1.59, ov; 1.42, ov 
3 42.2, CH2 1.38, dm (13.0);  
1.14, td (13.6, 4.1) 
42.2, CH2 1.37,  
dm (13.0); 1.13, ov 
42.2, CH2 1.37, dm (13.0);  
1.13, ov 
42.2, CH2 1.38, ov; 1.14, br 
t 
(13.6) 
4 33.4, CH2  33.4, CH2  33.4, CH2  33.4, CH2  
5 56.3, CH 0.91, dd (12.4, 2.4) 56.3, CH 0.90, ov 56.3, CH 0.91, br d (12.6) 56.28, CH 0.91, ov 
6 20.7, CH2 1.65, ov; 1.26, ov 20.7, CH2 1.64, ov; 1.26, ov 20.7, CH2 1.64, ov; 1.26, ov 20.68, CH2 1.65, ov; 1.26, ov 
7 44.7, CH2 
1.86, dt (12.3, 3.2); 
1.39, ov 
44.6, CH2 
1.86, dt (12.4, 3.2); 
1.38, ov 
44.6, CH2 
1.86, dt (12.3, 3.2); 
1.38, ov 
44.5, CH2 1.86, dt (12.4, 
3.4); 
1.39, ov 
8 74.5, C  74.6, C  74.4, C  74.39, C  
9 62.6, CH 1.00, br t (3.9) 62.6, CH 1.00, br t (3.8) 62.6, CH 1.00, br t (3.9) 62.5, CH 1.00, br t (3.9) 
10 39.3, C  39.3, C  39.3, C  39.29, C  
11 23.0, CH2 1.32, ov 23.1, CH2 1.31, ov 23.1, CH2 1.31, ov 23.0, CH2 1.37, ov; 1.28, ov 
12 41.2, CH2 1.46, ov; 1.23, ov 41.2, CH2 1.46, ov; 1.22, ov 41.2, CH2 1.46, ov; 1.22, ov 41.2, CH2 1.46, ov; 1.20, ov 
13 30.9, CH 1.53, ov 30.9, CH 1.51, ov 31.0, CH 1.51, ov 30.9, CH 1.51, ov 
14 35.6, CH2 1.70, ov; 1.48, ov 35.8, CH2 1.66, ov; 1.43, ov 35.8, CH2 1.66, ov; 1.44, ov 35.8, CH2 1.66, ov; 1.43, ov 
15 62.6, CH2 
4.25, ddd (11.0,  
7.6, 6.0);  
4.18 dt, (11.0, 7.0) 
62.8, CH2 
4.15, ddd (10.9,  
7.5, 6.0);  
4.06 dt, (10.9, 7.1) 
62.8, CH2 
4.14, ddd  
(11.0, 7.7, 6.0);  
4.06 dt, (11.0, 7.0) 





16 19.6, CH3 0.93, d (6.5) 19.6, CH3 0.91, d (6.5) 19.6, CH3 0.92, d (6.5) 19.6, CH3 0.92, d (6.5) 
17 24.1, CH3 1.14 s 24.1, CH3 1.13 s 24.1, CH3 1.14 s 24.1, CH3 1.14 s 
18 33.6, CH3 0.86 s 33.6, CH3 0.86 s 33.6, CH3 0.87 s 33.6, CH3 0.86 s 
19 21.6, CH3 0.79 s 21.6, CH3 0.78 s 21.7, CH3 0.79 s 21.7, CH3 0.78 s 
20 15.7, CH3 0.79 s 15.6, CH3 0.79 s 15.6, CH3 0.79 s 15.6, CH3 0.79 s 
1' 161.4, C 8.05 s 177.1, C  173.7, C  39.9, CH2 1.61, ov; 0.93, ov 
2'   41.3, CH 2.35, sext (7.0) 41.8, CH2 2.29, dd (14.6, 6.2); 
2.09, dd (14.6, 8.4) 
18.6, CH2 1.59, ov; 1.42, ov 
3'   26.9, CH2 1.67, ov; 1.44, ov 32.1, CH 1.87, ov 42.2, CH2 1.38, ov; 1.14, br 
t (13.6) 
4'   11.8, CH3 0.90, t (7.4) 29.5, CH2 1.36, ov; 1.22, ov 33.5, CH2  
5'   16.8, CH3 1.13, d (7.4) 11.4, CH3 0.89, t (7.3) 56.30, CH 0.91, ov 
6'     19.4, CH3 0.92, d (6.8) 20.72, CH2 1.65, ov; 1.26, ov 
7'       44.7, CH2 1.86, dt (12.4, 
3.4), 
1.39, ov 
8'       74.42, C  
9'       62.7, CH 1.00, br t (3.9) 
10'       39.32, C  
11'       20.3, CH2 1.37, ov; 1.28, ov 
12'       29.8, CH2 1.45, ov; 1.28, ov 
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13'       31.5, CH 1.92, oct (6.8) 
14'       41.9, CH2 2.30, dd (14.6, 
5.9); 2.14,  
dd (14.6, 7.9) 
15'       173.7, C  
16'       20.1, CH3 0.92, d (6.7) 
17       24.2, CH3 1.14 s 
18'       33.6, CH3 0.86 s 
19'       21.7, CH3 0.78 s 
20'       15.7, CH3 0.79 s 
aov : overlapped. 
 
The absolute configurations of the new compounds were not elucidated due to the paucity of each sample. 
However, the relative configuration could be assigned using the method of Carman,17 which established that 
the optical rotation value should give information about the structure and stereochemistry of the molecule.  
 
Figure 1. Key COSY (bold) and HMBC (blue arrows) correlations for compounds 1-4. 
 
This study on the empirical optical rotation values of labdane derivatives suggested that the optical rotation 
value should be the addition of the decalin ring portion and the lateral chain portion. However, application 
ofthis method did not allow a determination of the relative configurations of all new compounds, particularly 
for compound 1, where the lack of chiral center in the formate substituent did not permit the application of 
this procedure. Therefore, the relative configuration of these four new compounds has been established based 
on their NOESY spectra. Regarding the bicyclic ring, the relative configurations at C-5, C-8, C-9, and C-10 have to 
be defined. In their NOESY spectra, compounds 1-4 displayed the same NOE correlations for the decalin ring. 
The NOE cross-peaks H-20/H-17, H-20/ H-11, and H-5/H-9 and the lack of NOE correlations between H-20, H-17, 
H-11 and H-5, H-9 (Figure 2) suggested that the bicyclic ring configuration has to be normal- or ent-. The NOE 
correlations observed for these four new compounds were compared to those of the known isolated 
analogues: the NOE correlations were similar for all diterpenes isolated. 
 
As all the labdanes isolated were in the normal- configuration, it was considered that the configuration of 
decalin ring of all the new compounds is the same. Confirmation of the configuration in the decalin ring in each 
case was determined by comparison of observed correlations and chemical shifts of protons and carbons near 
the chiral centers with those of the known compounds: 13-epi-sclareol (7)12 and labdanolic acid.15 This 
information established the decalin ring as normal- configuration. However, configurations of chiral centers C-
13, C-2', C-3', and C-13' located on the lateral chains have not been established. 
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All the isolated compounds were tested for antiplasmodial activity against the 3D7 strain of Plasmodium 
falciparum (Table 2). Five of the known compounds exhibited moderate antiplasmodial activity: labdan-13(E)-
en-8α-ol-15-yl acetate (5), labdan-8α-ol-15-yl acetate (6), 13-epi-sclareol (7), labdan- 13(E)-ene-8α,15-diol (8), 
and (8R,13S)-labdane-8α,15-diol (9), with IC50 values of 29.1, 33.2, 35.0, 36.6, and 22.2 µM, respectively. 
 
Table 2. Antiplasmodial and Cytotoxic Activities of the Isolated Compounds 1-9 
compound P. falciparum (3D7) IC50 (µM)a 
labdan-8α-ol-15-yl-(formate) (1) 73.0 
labdan-8α-ol-15-yl-(2-methylbutanoate) (2) 58.0 
labdan-8α-ol-15-yl-(3-methylpentanoate) (3) 54.8 
labdan-8α-ol-15-yl-(labdanolate) (4) inactiveb 
labdan-13(E)-en-8α-ol-15-yl acetate (5) 29.1 
labdan-8α-ol-15-yl acetate (6) 33.2 
13-epi-sclareol (7) 35.0 
labdan-13(E)-ene-8α,15-diol (8) 36.6 
(8R,13S)-labdane-8α,15-diol (9) 22.2 
artemisinin 0.010 
 
aValues are the means ± standard deviations calculated from three independent assays in duplicate for antiplasmodial activity and two 
independent assays in triplicate for cytotoxicity activity. bInactive: IC50 > 50 µg∕mL. 
None of the compounds isolated is likely to be an antimalarial drug candidate because their IC50 values are in 
the µM range. However, these compounds could be used as starting materials for the semisynthesis of labdane 
derivatives with better antiplasmodial properties. Indeed, studies have suggested the relevance of a lactone or 
an endoperoxide group (such as artemisinin and its derivatives) to interfere with the parasite development.18'19 
The semisynthesis of labdane derivatives from manool and sclareol has been previously reported.19-21 
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GENERAL EXPERIMENTAL PROCEDURES 
Optical rotations were recorded on an Anton Paar MCP200 polarimeter. IR spectroscopic data were measured 
on a FTIR Bruker Tensor 27 spectrometer. NMR spectra were recorded in CDCl3 on a Bruker NMR spectrometer 
operating at 600 MHz for 1H and 150 MHz for 13C. The chemical shifts are given in δ (ppm) and coupling 
constants (J) are reported in Hz. The spectra were processed using 1D and 2D MestReNova (Mnova 12.0 
Mestrelab Research) software. HRESIMS were obtained on a SYNAPT G2 HDMS (Waters) TOF mass spectrometer 
in the positive-ion mode. 
Column chromatography was carried out using a glass column packed with Merck silica gel (0.040-0.063 mm; 
230-400 mesh). Semipreparative HPLC was carried out using Phenomenex Gemini C18 Prep (250 × 10 mm; i.d. 5 
µm) or Phenomenex Synergi hydro C18 Prep (250 × 10 mm; i.d. 5 µm) columns and was performed on Dionex 
Ultimate 3000 (Thermo Scientific) equipped with photodiode array detector (Thermo Scientific). Analytical 
HPLC was carried out using Gemini C18 (150 × 4.6 mm; i.d. 5 µm) or Synergi hydro C18 (150 × 4.6 mm; i.d. 5 µm) 
columns. All solvents were analytical or HPLC grade. 
PLANT MATERIAL 
 Psiadia arguta leaves were collected in the dry season in January 2015 in Mauritius (Réduit). A voucher 
specimen was deposited in the Herbarium of The University of Mauritius for identification, and the accession 
number MAU0018969 was attributed to the sample. Leaves were dried at 40 °C and kept at room temperature 
until processed. 
EXTRACTION AND ISOLATION 
 Dried and powdered leaves of P. arguta (110 g) were extracted exhaustively using an accelerated solvent 
extractor, ASE 300. Four successive extractions were carried out at 40 °C with EtOAc. The extract was 
evaporated under reduced pressure to yield about 12 g of crude extract. Nine grams of the crude extract was 
fractionated by column chromatography on normal-phase silica gel 60 (35 × 5 cm) using combinations of n-
hexane, EtOAc, and MeOH of increasing polarity. Altogether, 18 fractions were obtained. All fractions were 
evaluated for their antiplasmodial activity against P. falciparum. The active fractions found were fractions F4, 
F6, F7, and F9 (IC50 = 16.3, 8.8, 13.9, and 9.8 µg/mL, respectively), and fractions containing major compounds 
were fractions F11, F14, F15, and F18. Fraction 4 was subjected to semipreparative HPLC (Synergi hydro 5 µm, 
250 × 10 mm i.d.), 4.5 mL min-1 isocratic elution with 95% MeOH-H2O (+0.1% formic acid) over 2 min, followed 
by 97% MeOH-H2O over 2 min, then 99% MeOH-H2O  over 1 min and maintained at 100% MeOH over 20 min (UV 
210 nm). The purification of fraction 4 led to isolation of pure compounds labd- 8(20)-en-15-ol (1.3 mg, tR 16.5 
min) and α-amyrin (2.6 mg, tR 15 min). Fraction 4 was further purified by CC on silica gel (30 × 2.5 cm), using a 
gradient of n-hexane-EtOAc (100:0 to 0:100, v/v) as mobile phase and gave 14 fractions. Subfraction F4-f2 was 
subjected to semipreparative HPLC (Gemini C18 prep column, 5 µm, 250 × 10 mm i.d.), 5 mL min-1 isocratic 
elution with 95% MeOH-H2O (+0.1% formic acid) over 2 min and elution gradient to 100% MeOH (+0.1% formic 
acid) over 10 min and maintained at 100% MeOH over 18 min; UV 210 nm. Pure compounds β-amyrin (3.7 mg, tR 
18.6 min) and α-amyrin (8.2 mg, tR 19.8 min) were thus obtained. The purification of subfraction F4-f6 was 
performed by semipreparative HPLC (Gemini C18 prep column, 5 µm, 250 × 10 mm i.d.), 5 mL min-1 gradient 
elution with 90% MeOH--H2O (+0.1% formic acid) to 100% over 10 min and maintained at 100% MeOH over 25 
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Fraction 6 was subjected to semipreparative HPLC (Gemini C18 prep column, 5 µm, 250 × 10 mm i.d.), 5 mL min-1 
gradient elution with 85% MeOH-H2O (+0.1% formic acid) to 92.5% MeOH-H2O (+0.1% formic acid) over 15 min 
(UV 210 nm), and furnished pure compounds 5 (3.7 mg, tR 11.5 min), 6 (5.7 mg, tR12.9 min), and 1 (1.4 mg, tR12.3 
min).  
Purification of fraction 7 was performed by semipreparative HPLC (Gemini C18 prep column, 5 µm, 250 × 10 mm 
i.d.), 4 mL min-1 isocratic elution with 92% MeOH-H2O (+0.1% formic acid) over 5 min and gradient elution with 
92% MeOH-H2O (+0.1% formic acid) to 100% MeOH-H2O (+0.1% formic acid) over 10 min (UV 210 nm). Fraction 7 
afforded pure compound anticopalic acid (1.7 mg, tR 9.9 min). Fraction 9 was applied to semipreparative HPLC 
(Gemini C18 prep column, 5 µm, 250 × 10 mm i.d.), 5.5 mL min-1, and eluted by a 85% to 100% MeOH-H2O (+0.1% 
formic acid) gradient over 30 min to yield physanicandiol and 14-epi-physanicandiol (mixture 50:50, 1.7 mg, tR 
9.5 min) and 4 (1.8 mg, tR 25.5 min). Fraction 11 was submitted to CC on silica gel (18 × 1.5 cm, 230-400 mesh), 
using a gradient of n- hexane-EtOAc (100:0 to 40:60) as mobile phase. The purification afforded compound 7 (6 
mg). Fraction 14 was purified by CC on silica gel (20 × 1.5 cm, 230-400 mesh), using a gradient of n- hexane-
EtOAc (75:25 to 50:50) as mobile phase to give pure compound 8 (1.65 mg). Fraction 15 yielded compound 9 
(0.5 g) without further purification. Fraction 18 was purified by CC on silica gel (12 × 3 cm, 230-400 mesh), using 
a gradient of n-hexane-EtOAc (50:50 to 10:90) as mobile phase to give pure labdanolic acid (9 mg). 
Labdan-8α-ol-15-yl-(formate) (1): green oil; [α]D5 -78 (c 0.11, CHCl3); IR (ATR) νmax 3436, 2928, 2869, 1728, 1460, 
1387, 1365, 1173 cm-1; 1H and 13C NMRdata, Table 1; HRESIMS m/z 361.2713 [M + Na]+ (calcd for C21H38O3Na, 
361.2713). 
Labdan-8α-ol-15-yl-(2-methylbutanoate) (2): colorless oil; [α]D5 -9 (c 1.17, CHCl3); IR (ATR) νmax 3504, 2927, 2869, 
2855, 1734, 1719, 1461, 1386, 1365, 1261, 1184, 756 cm-1; 1H and 13C NMR data, Table 1; C25H46O3; HRESIMS m/z 
417.3337 [M + Na]+ (calcd for C25H46O3Na, 417.3339). 
Labdan-8α-ol-15-yl-(3-methylpentanoate) (3): colorless oil; [α]D5 -6 (c 0.64, CHCl3); IR (ATR) νmax 3505, 2959, 2929, 
2872, 1721, 1461, 1387, 1365, 1260, 1183, 755 cm-1; 1H and 13C NMR data, Table 1; C26H48O3; HRESIMS m/z 
431.3493 [M + Na]+ (calcd for C26H48O3Na, 431.3496). 
Labdan-8α-ol-15-yl-(labdanolate) (4): green gum; [α]D5 +6 (c 0.34, CHCl3); IR (ATR) νmax 3447, 2927, 2854, 1717, 
1459, 1388, 1260, 1183, 755 cm-1; 1H and 13C NMR data, Table 1; HRESIMS m/ z 639.5328 [M + Na]+ (calcd for 
C40H72O4Na, 639.5323). 
IN VITRO ANTIPLASMODIAL ASSAYS 
 The effect of each fraction and pure compound on parasite growth of the P. falciparum strain 3D7 was 
measured in a 48 h growth assay as previously reported.22,23 Briefly, ring-stage parasite cultures were grown for 
48 h in the presence of increasing concentration of drug at 37 °C. After 48 h in culture, parasite viability was 
determined by the APAD colorimetric test. The half inhibitory concentration (IC50) values are the average of 
three independent assays with each determination in duplicate and are expressed as means ± SEM. 
ASSOCIATED CONTENT 
SUPPORTING INFORMATION 
The Supporting Information is available free of charge on the ACS Publications website at DOI: 
10.1021/acs.jnatprod.8b00698. 
HRESIMS, IR (FT-IR), and 1D and 2D NMR spectra for 1-4 (PDF) 
 
 
Published in : Journal (année), vol. xx, n°xx, pp. xx–xx 
DOI:xxxxxxxxxxxxxxx 







Gaetan Herbette: 0000-0002-3374-2508 
Anne Gauvin-Bialecki: 0000-0001-5188-0704 
Notes 
The authors declare no competing financial interest. 
ACKNOWLEDGMENTS 
The financial supports from Regional Council of Reunion Island and from the Belgian Fund for Scientific 
Research (grant T.0190.13) are gratefully acknowledged. 
 
REFERENCES 
(1) Bosser, J.; Guého, J.; Jeffrey, C. In Flore Des Mascareignes. La Réunion, Maurice, Rodrigues; The Sugar Industry 
Research Institute, Mauritius, L’Institut Francais de Recherche Scientifique pour le Développement en Coopération 
(ORSTOM); Paris, The Royal Botanic Gardens, Kew, 1993. 
(2) Sussman, L. K. J. Ethnopharmacol. 1980, 2, 259-278. 
(3) Wang, Y.; Hamburger, M.; Gueho, J.; Hostettmann, K. Helv. Chim. Acta 1992, 75, 269-275. 
(4) Kauroo, S.; Govinden-Soulange, J.; Marie, D. E. P. Int. J. Chem. Environ. Biol. Sci. 2016, 4, 23-27. 
(5) Recio, M. C.; Giner, R. M.; Mánez, S.; Rios, J. L.; Marston, A.; Hostettmann, K. Phytother. Res. 1995, 9, 571-574. 
(6) Jonville, M. C.; Kodja, H.; Strasberg, D.; Pichette, A.; Ollivier, E.; Frédérich, M.; Angenot, L.; Legault, J.  
J. Ethnopharmacol. 2011, 136, 525-531. 
(7) Dias, M. O.; Hamerski, L.; Pinto, A. C. Quim. Nova 2011, 34, 704-706. 
(8) Urones, J. G.; Marcos, I. S.; Cubillo, L.; Monje, V. A.; Hernández, J. M.; Basabe, P. Phytochemistry 1989, 28, 651-653. 
(9) Urones, J. G.; Basabe, P.; Marcos, I. S.; Díez Martin, D.; Sexmero, M. J.; Peral, M. H.; Broughton, H. B. Tetrahedron 
1992, 48, 10389-10398. 
(10) Cavin, A.-L.; Hay, A.-E.; Marston, A.; Stoeckli-Evans, H.; Scopelliti, R.; Diallo, D.; Hostettmann, K. J. Nat. Prod. 2006, 
69, 768-773. 
(11) Maldonado, E.; Pérez-Castorena, A. L.; Romero, Y.; Martínez, M. J. Nat. Prod. 2015, 78, 202-207. 
(12) Yang, X.-W.; Feng, L.; Li, S.-M.; Liu, X.-H.; Li, Y.-L.; Wu, L.; Shen, Y.-H.; Tian, J.-M.; Zhang, X.; Liu, X.-R. Bioorg. Med. 
Chem. 2010, 18, 744-754. 
 
 
Published in : Journal (année), vol. xx, n°xx, pp. xx–xx 
DOI:xxxxxxxxxxxxxxx 





(13) Forster, P. G.; Ghisalberti, E. L.; Jefferies, P. R. Phytochemistry 1985, 24, 2991-2993. 
(14) Pascual Teresa, J. D.; Urones, J. G.; Marcos, I. S.; Núñez, L.; Basabe, P. Phytochemistry 1983, 22, 2805-
2808. 
(15) Castro, J. M.; Salido, S.; Altarejos, J.; Nogueras, M.; Sánchez, A. Tetrahedron 2002, 58, 5941-5949. 
(16) Weyerstahl, P.; Marschall, H.; Weirauch, M.; Thefeld, K.; Surburg, H. Flavour Fragrance J. 1998, 13, 295-
318. 
(17) Carman, R. Aust. J. Chem. 1966, 19, 629-642. 
(18) Cheikh-Ali, Z.; Okpekon, T.; Roblot, F.; Bories, C.; Cardao, M.; Jullian, J.-C.; Poupon, E.; Champy, P. 
Phytochem. Lett. 2011, 4, 240-244. 
(19) Villamizar, J.; Pittelaud, J. P.; Rodrigues, J. R.; Gamboa, N.; Canudas, N.; Tropper, E.; Salazar, F.; 
Fuentes, J. Nat. Prod. Res. 2009, 23, 891-902. 
(20) Villamizar, J.; Fuentes, J.; Salazar, F.; Tropper, E.; Alonso, R. J. Nat. Prod. 2003, 66, 1623-1627. 
(21) Grant, P. K.; Chee, K. L.; Prasad, J. S.; Tho, M. Y. Aust. J. Chem. 1988, 41, 711-725. 
(22) Jansen, O.; Tits, M.; Angenot, L.; Nicolas, J.-P.; De Mol, P.; Nikiema, J.-B.; Frédérich, M. Malar. J. 2012, 
11, 289. 
(23) Fidock, D. A.; Rosenthal, P. J.; Croft, S. L.; Brun, R.; Nwaka, S. Nat. Rev. Drug Discovery 2004, 3, 509-520. 
 
